Delayed initiation of remdesivir beneficial for COVID‐19, neutrophil-to-lymphocyte ratio predicts mortality in hospitalised patients with COVID-19, and arbidol monotherapy for COVID-19
In today’s DG Alert, we cover late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), neutrophil-to-lymphocyte ratio (NLR) as an independent risk factor for mortality in hospitalised patients with coronavirus…